Roche has lost the fast track status it won for the EU marketing application it filed with the European Medicines Agency last October for satralizumab, the drug it is developing to treat the rare disease neuromyelitis optica spectrum disorder (NMOSD).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?